You have been working in the life science and healthcare sector for more than fifteen years. What makes this work so appealing?
The sector has its own special challenges. On the one hand, the costs for drug development are significant and the development itself is highly regulated...
Our Phase II clinical trial in psoriasis is almost completed. And we are especially interested in one question: Has the good safety profile from our previous studies been confirmed? Nobody wants avoidable side effects. But does it really make sense that we place so much emphasis on a good safety profile in the development of MP1032?
When I started working in medical research, m...
Is there a problem with increasing life expectancy? If you look at the graph of average life years alone, the development over the last fifty years looks very positive. This graph shows a steady upward trend, especially in Western countries. People are getting older continuously.
There is, however, a second graph that has risen much slower: that of healthy life expectancy...
Do you remember first hearing about MetrioPharm?
Yes, I do remember. I have a friend, who told me to take a look at this company. I reviewed their data and the first thing I liked was the unique profile of the MP1032 platform...
Dr. Wolfgang Brysch
For this blog entry, we’ve been thinking: Is there a question that has been asked most frequently this year? And what does the answer say about our work at MetrioPharm?
The most frequently asked question clearly was: “Is MetrioPharm working on InflammAging?”
The so-call...
Dr. Petra Schulz, Senior Manager Drug Development at MetrioPharm spoke to us about the ongoing Phase II clinical trial and the details of the current press release
Photo: © F. Edler
MetrioPharm’s lead compound MP1032 entered Phase II clinical testing in early March. How has the study gone so far?
Dr. Petra Schulz: The most important goal of a large Phase II study continues to be to test the safety of the drug, i.e. whether the patients tolerate it well. So far, nobody has had to discontinue the study after taking MP1032, which is a good signal. The other important objectives – proof of efficacy and the search for the optimal dosage – are still unknown, because at the moment the study is blinded.
This week there was a...
The 19th Meeting of the Society for Free Radical Research International 2018 in Lisbon
What is the most important step in the development of a new drug? The successful completion of preclinical trials, the first clinical study in humans or the proof of efficacy in patients? All these steps are a precondition for approval; they show that the drug works...
A recent study investigates the correlation between chronic inflammation and Alzheimer’s disease.
Foto: © Fotolia
In our last blog entry, our CEO Dr. Wolfgang Brysch replied to the question: “Does MetrioPharm have competition? You can find the full article here. In this article we take a closer look at a drug that has already been tested.
If a patient suffers from an autoimmune disease, for example psoriasis, his physician ...
Dr. Wolfgang Brysch
Actually, it’s a routine question and I could have expected it. I was asked at our anniversary celebration last fall: “10 years of MetrioPharm – which one was the most difficult?” I had to think about that question for a moment. The year 2007 is not far in the past, still the difficulties of that time feel oddly distant now.
In 2008, right after the founding of the company, we were in...
Dr. Beate Ludescher is Head of Regulatory Affairs. She joined MetrioPharm in 2007. Dr. Sara Schumann is a Project Manager for Research and Development, she joined the team in October 2017.
Photo: © Eva Brysch, 2018
You are at a party: how do you explain what you do for a living?
Dr. Beate Ludescher: Difficult, this is a struggle I have at...
© MetrioPharm AG 2019
